Axogen names Lindsey Hartley as new CFO

ALACHUA, Fla. - Axogen, Inc. (NASDAQ: AXGN), a company specializing in surgical solutions for peripheral nerve injuries with a market capitalization of $746 million and an impressive 179% stock return over the past year, announced the appointment of Lindsey Hartley as its new Chief Financial Officer, effective May 12, 2025. According to InvestingPro data, analysts have set price targets ranging from $24 to $30, suggesting significant upside potential. Hartley, currently the Vice President and Corporate Controller at Axogen, will take over from Nir Naor, who is stepping down to pursue other opportunities. Naor will continue in an advisory role until July 1, 2025, to assist with the transition.

The company’s President and CEO, Michael Dale, praised Naor for his contributions, particularly in improving operating expense management and cash flow, as well as supporting the development of Axogen’s strategic plan. Dale also expressed confidence in Hartley’s abilities, citing her deep understanding of the business and strong financial acumen as key factors in her promotion.

Hartley has more than 19 years of experience in financial leadership, with a focus on corporate finance, accounting, and financial reporting in the healthcare and medical device sectors. Since joining Axogen in October 2021, she has made significant improvements to the company’s financial reporting processes, including a 40% reduction in month-end close time and enhanced cash forecasting capabilities. The company maintains strong financial health with a current ratio of 3.24 and has achieved 17.81% revenue growth over the last twelve months. InvestingPro analysis reveals 12 additional key insights about Axogen’s financial position and growth prospects.

Before Axogen, Hartley held various leadership roles, including positions at VERO Biotech, Brookhaven Medical, Bluegreen Vacations, and as an audit manager at EY. She holds a Bachelor of Science in Accounting from the University of South Florida and is a Certified Public Accountant.

Hartley expressed her honor in stepping into the CFO role and her commitment to financial discipline and strategic growth initiatives that support Axogen’s mission to restore nerve function and improve patients’ lives.

Axogen is recognized for its dedication to the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. Its portfolio includes a range of products available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and other countries. With net income expected to grow this year and analysts predicting profitability, the company shows promising potential. For detailed analysis and comprehensive insights, including Fair Value estimates and growth projections, investors can access the full Pro Research Report available on InvestingPro.

This announcement is based on a press release statement issued by Axogen on May 8, 2025. The company’s forward-looking statements are subject to various risks and uncertainties, as detailed in their SEC filings.

In other recent news, AxoGen, Inc. reported sales of $49.4 million, reflecting a 15.1% increase year over year, surpassing prior estimates. The company has set a revenue growth forecast of 15-17% for 2025, translating to $215.4 million to $219.1 million, which is approximately $11 million above JMP Securities’ expectations. Analysts at Lake Street Capital Markets initiated coverage of AxoGen with a Buy rating and a price target of $30, citing the company’s solid foundation for growth and potential for positive cash flow by 2025. Cantor Fitzgerald maintained an Overweight rating with a $24 price target, highlighting AxoGen’s strategic plan to increase adoption and penetrate new markets. Citizens JMP analyst David Turkaly reiterated a Market Outperform rating and raised the price target to $26, anticipating a significant advantage from the upcoming Biologics License Application approval for the Avance Nerve Graft. This approval is expected to grant AxoGen’s product 12+ years of market exclusivity, enhancing its competitive position. AxoGen’s strategic initiatives and financial performance have drawn positive attention from multiple analyst firms, reflecting confidence in its growth prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.